Sight Sciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $83.4M+4.4% YoYTTM through 30 Jun 2026
Net Income -$29.8MTTM through 30 Jun 2026
Free Cash Flow -$23.3MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 86.0% |
| EBITDA Margin | -32.9% |
| Operating Margin | -47.9% |
| Net Margin | -35.7% |
Returns
-60.1%ROE
-33.3%ROA
Balance Sheet Health
Debt / Equity0.63x
Current Ratio10.22x
Net Debt-$51.7Mnet cash position
Cash & Equivalents$79.8M
Quality Metrics
Altman Z-Score0.94
Piotroski F-Score5 / 9
FCF Margin-28.0%
Rule of 40-24.8
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $77.4M
Diluted EPS-$0.55TTMFY2025: $-0.74
Dividend
No dividend
Capital Allocation
R&D Spend$10.8M
Capex Intensity0.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Interventional Glaucoma | $75.7M | 0.0% | View detailsExpected to grow 2% to 7% in full year 2026, reaching a range of $77.0 million to $81.0 million. |
| Interventional Dry Eye | $16M | -60.0% | View detailsExpected to scale significantly in full year 2026 to a range of $5.0 million to $7.0 million, driven by expanded market access and reimbursement wins. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.